Harvard Thoracic Pathology 2024

Overview

The Harvard Thoracic Pathology 2024 course provides a comprehensive overview of thoracic pathology, integrating clinical, radiologic, and molecular perspectives. Originally presented by experts from Massachusetts General Hospital and Memorial Sloan Kettering Cancer Center, this program offers detailed updates in diagnostic criteria, staging, and molecular analysis of thoracic diseases. On-demand pulmonology education — accessible anytime, anywhere.

Agenda

This virtual course encompasses a three-day program recorded in Eastern Time, featuring didactic lectures, case-based presentations, multidisciplinary sessions, and interactive discussions led by recognized specialists in thoracic pathology and related fields.

• Opening Remarks — Mari Mino-Kenudson, MD
• Updates in Classification and Diagnosis in Lung Cancer — William D. Travis, MD
• Therapeutic Relevant Molecular Subsets of Lung Cancer — A. John Iafrate, MD, PhD
• Current Update in Thoracic Oncology: Implications for Pathologists — Zofia Piotrowska, MD
• What Does a Thoracic Surgeon Want to Know from Pathologists? — Hugh Auchincloss, MD, MPH
• Q&A Session
• Break
• Immunohistochemistry for Lung Cancer Diagnosis — Natasha Rekhtman, MD, PhD
• Minimally Invasive Endobronchial Techniques, Including Ion Robot Bronchoscopy — Colleen Keyes, MD
• Diagnosis of Lung Cancer in Small Biopsies and Cytology — Paul VanderLaan, MD, PhD
• Immunohistochemistry for Predictive Markers in Lung Cancer — Mari Mino-Kenudson, MD
• Q&A Session
• Lunch Break
• Staging of Lung Cancer — Natasha Rekhtman, MD, PhD
• Radiologic Pathologic Correlations in Thoracic Neoplasia — Subba Digumarthy, MD
• Variants of Lung Adenocarcinoma and Squamous Cell Carcinoma — Mari Mino-Kenudson, MD
• Q&A Session
• Break
• Neuroendocrine Tumors of the Lung — Natasha Rekhtman, MD, PhD
• Update on IASLC/AMP/CAP Molecular Guidelines on Lung Tumor — Lynette Sholl, MD
• Tumor Board Discussion — Ibiayi Dagogo-Jack, MD; Mari Mino-Kenudson, MD; Melissa Price, MD; Michael Lanuti, MD
• Q&A Session
• Pathology of Interstitial Lung Disease — William D. Travis, MD
• Radiology of Interstitial Lung Disease — Amita Sharma, MD
• Clinical Profile of Interstitial Lung Disease — Barry Shea, MD
• Pathology of Interstitial Lung Disease II — William D. Travis, MD
• Q&A Session
• Break
• The Spectrum of Hypersensitivity Reactions in the Lung — Lida Hariri, MD, PhD
• Lung Manifestations of Systemic Disorders (including IgG4-Related Diseases and Vasculitis) — Mary Beth Beasley, MD
• The Pathologist’s Role in Multidisciplinary Discussion for Interstitial Lung Disease — Lida Hariri, MD, PhD
• Multidisciplinary Approach to Interstitial Lung Disease — Lida Hariri, MD, PhD; Amita Sharma, MD; Barry Shea, MD
• Q&A Session
• Lunch Break
• Diagnostic Approach to Acute Lung Injury — Mary Beth Beasley, MD
• COVID-Related Lung Disease — Mari Mino-Kenudson, MD
• Pathology of Lung Transplantation — Marina Vivero, MD
• Q&A Session
• Break
• Tumor-Like Lesions of the Lung — Mari Garcia Moliner, MD
• Pulmonary Infection — Angela Shih, MD
• Pitfalls in Intraoperative Consultation and QA Issues of Thoracic Diseases — Angela Shih, MD
• Q&A Session
• Malignant Mesothelioma — Lucian Chirieac, MD
• Unusual Mediastinal and Thoracic Epithelial Tumors (NUT, SMARCA4, Germ Cell, Other) — Yin (Rex) Hung, MD, PhD
• Thymomas and Their Differential Diagnoses — Yin (Rex) Hung, MD, PhD
• Pulmonary and Mediastinal Lymphomas — Aliyah Sohani, MD
• Q&A Session
• Break
• Tumors of Trachea and Salivary Gland-Type Tumors — Michiya Nishino, MD, PhD
• Thoracic Soft Tissue Tumors — Yin (Rex) Hung, MD, PhD
• Mystery Cases — Angela Shih, MD; Igor Odintsov, MD
• Q&A Session
• Closing Remarks and Adjourn — Mari Mino-Kenudson, MD

Learning Objectives

Upon completion of this activity, participants will be able to:

• Evaluate individual tests and their tissue requirements for clinical management of advanced lung cancer patients.
• Apply the updated staging guidelines for lung cancer.
• Analyze current diagnostic criteria for mesothelioma, including a clinicopathological staging system.
• Determine when to apply the international guidelines for the care of patients with interstitial lung disease.

Speakers

This course features distinguished faculty including thoracic and molecular pathologists, thoracic radiologists, surgeons, oncologists, and pulmonologists from leading academic medical centers such as Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, and Brigham and Women’s Hospital. These experts provide interdisciplinary insights essential for thoracic pathology practice.

Target Audience

• Pathologists
• Pulmonologists
• Thoracic Surgeons
• Radiologists
• Specialty Physicians
• Physician Assistants
• Nurse Practitioners
• Industry Professionals

Why This Topic Matters

The Harvard Thoracic Pathology 2024 course addresses critical advances and diagnostic challenges in thoracic pathology, facilitating enhanced expertise in lung cancer, interstitial lung disease, and other thoracic disorders. Covering the latest diagnostic techniques and multidisciplinary approaches, this program supports pulmonology professionals in refining clinical decision-making.

MedHub Central provides access to this comprehensive educational resource, reinforcing thoracic pathology knowledge to support confident evaluation and management of complex thoracic diseases in both academic and community settings.